2. Academic Validation
  3. In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

In Vitro and In Vivo Activities of Contezolid (MRX-I) against Mycobacterium tuberculosis

  • Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00493-18. doi: 10.1128/AAC.00493-18.
Carolyn Shoen 1,  Michelle DeStefano 2,  Barry Hafkin 3,  Michael Cynamon 1 4
Affiliations

Affiliations

  • 1 Central New York Research Corporation, Syracuse, New York, USA shoenc@cnyrc.org Michael.Cynamon@va.gov.
  • 2 Central New York Research Corporation, Syracuse, New York, USA.
  • 3 MicuRx Pharmaceuticals, Hayward, California, USA.
  • 4 Veterans Affairs Medical Center, Syracuse, New York, USA.
PMID: 29784848 DOI: 10.1128/AAC.00493-18
Abstract

The in vitro activity of contezolid (MRX-I) against clinical isolates of Mycobacterium tuberculosis was evaluated using a microtiter broth dilution assay. MRX-I was as effective as linezolid (LZD) in vitro MRX-I and LZD were subsequently studied in BALB/c mice infected intranasally with M. tuberculosis Erdman. MRX-I and LZD at 100 mg/kg significantly reduced the Bacterial load in lungs compared to the untreated early and late controls.

Keywords

Mycobacterium tuberculosis; in vitro; mouse model; oxazolidinones.

Figures
Products